Medicus Pharma advances pipeline during Q2 with key milestones
Yahoo Finance · Aug 13, 2026 · Medicus Pharma Ltd. Warrant (MDCXW)
Medicus Pharma (NASDAQ:MDCX) has reported second quarter financial results and regulatory and clinical progress across its SkinJect and Teverelix programs, while raising about $40 million through equity and debt financing during the first half of 2026. The company said it received FDA “Study...
Not investment advice. Cached headline, not a full reprint.